EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
June 10, 2009
EyeGate Pharma announced last week that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES) in a Phase II study.
The Phase II single-center, randomized (105 patients), double-masked, placebo-controlled patient study evaluated the safety and efficacy of a corticosteroid solution (EGP-437) administered by the EyeGate® II Delivery System (at two dose levels) twice over a three-week period.
In the top-level analysis, investigators observed that EGP-437 significantly (p < 0.05) improved signs and symptoms of DES during the three-week environmental component, which included three CAE exposures and two doses. EGP-437 also improved signs and symptoms when studied as a treatment and preventative in conjunction with the CAE.
Read the full release.
You might also enjoy...
- ISTA Pharmaceuticals Reports Results of Studies of REMURA(TM) Eye Drops for Dry Eye Disease
- Resolvyx Announces Positive Data from Trial of Resolvin RX-10045 for Dry Eye
- LipiFlow® Thermal Pulsation System Effectively Treats Meibomian Gland Dysfunction
- Volunteers With Dry Eye Sought for Clinical Trial to Evaluate Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution to Treat Dry Eye
- How Does Temperature Affect Dry Eye?
Jump down to form below to submit your own comments